Quantitative β-Cell Mass Imaging Redefines Disease Staging and Glycemic Control in Type 1 Diabetes - PubMed
7 hours ago
- #Type 1 Diabetes
- #18F-exendin PET/CT
- #β-Cell Mass Imaging
- Study addresses the need for noninvasive β-cell mass assessment in type 1 diabetes.
- 18F-exendin PET/CT reliably visualizes residual β-cell mass and differentiates disease stages.
- Pancreatic tracer uptake is reduced in type 1 diabetes and correlates with β-cell function and glycemic status.
- 18F-exendin imaging could be a platform for disease staging, therapy monitoring, and personalized care.